INTRODUCTION: Data on enhanced recovery programmes after pancreatoduodenectomy (ERP-PD) is limited. The aim of this pilot study was to evaluate the feasibility, safety and clinical outcomes of ERP-PD when implemented at a high-volume UK university referral centre. METHODS: This was an observational single-surgeon case-control study (before-and-after pathway). A total of 20 consecutive patients were prospectively enrolled for the ERP-PD and compared with 24 consecutive patients previously treated during an equal time frame. RESULTS: Patients in the ERP-PD group had a significant shorter time to remove naso-gastric tube (median of 5 vs. 7 days, p = 0.0001), start liquid diet (median of 2 vs. 5 days, p < 0.0001), start solid food (median of 4 vs. 9 days, p < 0.0001), pass stools (median of 6 vs. 7 days, p = 0.002), and had shorter length of stay (median of 8.5 days vs. 13 days, p = 0.015) compared to the pre-pathway group. Postoperative complications were overall less frequent but not significantly different in the ERP-PD group (p = 0.077). No difference in mortality and readmission rates was found. CONCLUSIONS: Our findings support the feasibility and safety of ERP-PD. Improved patients' outcomes, significant bed day savings and increase National Health Service productivity are anticipated with implementation of ERP-PD on a larger scale.
INTRODUCTION: Data on enhanced recovery programmes after pancreatoduodenectomy (ERP-PD) is limited. The aim of this pilot study was to evaluate the feasibility, safety and clinical outcomes of ERP-PD when implemented at a high-volume UK university referral centre. METHODS: This was an observational single-surgeon case-control study (before-and-after pathway). A total of 20 consecutive patients were prospectively enrolled for the ERP-PD and compared with 24 consecutive patients previously treated during an equal time frame. RESULTS:Patients in the ERP-PD group had a significant shorter time to remove naso-gastric tube (median of 5 vs. 7 days, p = 0.0001), start liquid diet (median of 2 vs. 5 days, p < 0.0001), start solid food (median of 4 vs. 9 days, p < 0.0001), pass stools (median of 6 vs. 7 days, p = 0.002), and had shorter length of stay (median of 8.5 days vs. 13 days, p = 0.015) compared to the pre-pathway group. Postoperative complications were overall less frequent but not significantly different in the ERP-PD group (p = 0.077). No difference in mortality and readmission rates was found. CONCLUSIONS: Our findings support the feasibility and safety of ERP-PD. Improved patients' outcomes, significant bed day savings and increase National Health Service productivity are anticipated with implementation of ERP-PD on a larger scale.
Authors: Arja Gerritsen; Roos A W Wennink; Marc G H Besselink; Hjalmar C van Santvoort; Dorine S J Tseng; Elles Steenhagen; Inne H M Borel Rinkes; I Quintus Molenaar Journal: HPB (Oxford) Date: 2013-12-06 Impact factor: 3.647
Authors: Marion van der Kolk; Mark van den Boogaard; Femke Becking-Verhaar; Hettie Custers; Hans van der Hoeven; Peter Pickkers; Kees van Laarhoven Journal: J Gastrointest Surg Date: 2017-06-06 Impact factor: 3.452
Authors: Jason W Denbo; Morgan Bruno; Whitney Dewhurst; Michael P Kim; Ching-Wei Tzeng; Thomas A Aloia; Jose Soliz; Barbara Bryce Speer; Jeffrey E Lee; Matthew H G Katz Journal: Surgery Date: 2018-05-25 Impact factor: 3.982
Authors: Robert P Sutcliffe; Majd Hamoui; John Isaac; Ravi Marudanayagam; Darius F Mirza; Paolo Muiesan; John K Roberts Journal: World J Surg Date: 2015-08 Impact factor: 3.352